Oculis Holding AG Logo

Oculis Holding AG

OCS

(1.5)
Stock Price

16,98 USD

-52.83% ROA

-73.13% ROE

-7.85x PER

Market Cap.

540.427.724,08 USD

1.19% DER

0% Yield

-10678.07% NPM

Oculis Holding AG Stock Analysis

Oculis Holding AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oculis Holding AG Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (20.48%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-2.87x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-126%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 ROA

The stock's ROA (-77%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Oculis Holding AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oculis Holding AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Oculis Holding AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oculis Holding AG Revenue
Year Revenue Growth
2020 993.000
2021 960.000 -3.44%
2022 912.000 -5.26%
2023 0 0%
2023 883.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oculis Holding AG Research and Development Expenses
Year Research and Development Expenses Growth
2020 9.337.000
2021 9.568.000 2.41%
2022 22.224.000 56.95%
2023 35.488.000 37.38%
2023 29.247.000 -21.34%
2024 65.860.000 55.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oculis Holding AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2020 3.515.000
2021 4.097.000 14.21%
2022 6.743.000 39.24%
2023 14.588.000 53.78%
2023 17.487.000 16.58%
2024 20.852.000 16.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oculis Holding AG EBITDA
Year EBITDA Growth
2020 -12.097.000
2021 -12.976.000 6.77%
2022 -31.951.000 59.39%
2023 -49.464.000 35.41%
2023 -45.726.000 -8.17%
2024 -86.944.000 47.41%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oculis Holding AG Gross Profit
Year Gross Profit Growth
2020 -8.344.000
2021 -8.608.000 3.07%
2022 -21.312.000 59.61%
2023 0 0%
2023 -28.364.000 100%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oculis Holding AG Net Profit
Year Net Profit Growth
2020 -14.873.000
2021 -18.552.000 19.83%
2022 -38.698.000 52.06%
2023 -69.652.000 44.44%
2023 -88.802.000 21.56%
2024 -83.356.000 -6.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oculis Holding AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2020 0
2021 -1 0%
2022 -1 100%
2023 -2 0%
2023 -3 50%
2024 -2 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oculis Holding AG Free Cashflow
Year Free Cashflow Growth
2020 -12.048.000
2021 -13.853.000 13.03%
2022 -28.622.000 51.6%
2023 -11.998.000 -138.56%
2023 -53.893.000 77.74%
2024 -13.515.000 -298.76%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oculis Holding AG Operating Cashflow
Year Operating Cashflow Growth
2020 -12.029.000
2021 -13.825.000 12.99%
2022 -25.074.000 44.86%
2023 -11.979.000 -109.32%
2023 -53.845.000 77.75%
2024 -13.515.000 -298.41%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oculis Holding AG Capital Expenditure
Year Capital Expenditure Growth
2020 19.000
2021 28.000 32.14%
2022 3.548.000 99.21%
2023 19.000 -18573.68%
2023 48.000 60.42%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oculis Holding AG Equity
Year Equity Growth
2020 -43.654.000
2021 -60.955.000 28.38%
2022 -97.991.000 37.8%
2023 93.728.000 204.55%
2023 105.603.000 11.24%
2024 112.826.000 6.4%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oculis Holding AG Assets
Year Assets Growth
2020 16.383.000
2021 58.043.000 71.77%
2022 37.060.000 -56.62%
2023 114.353.000 67.59%
2023 128.941.000 11.31%
2024 138.732.000 7.06%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oculis Holding AG Liabilities
Year Liabilities Growth
2020 60.037.000
2021 118.998.000 49.55%
2022 135.051.000 11.89%
2023 20.625.000 -554.79%
2023 23.338.000 11.62%
2024 25.906.000 9.91%

Oculis Holding AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.02
Net Income per Share
-1.65
Price to Earning Ratio
-7.85x
Price To Sales Ratio
863.3x
POCF Ratio
-10.15
PFCF Ratio
-10.45
Price to Book Ratio
4.65
EV to Sales
795.39
EV Over EBITDA
-8.27
EV to Operating CashFlow
-9.63
EV to FreeCashFlow
-9.63
Earnings Yield
-0.13
FreeCashFlow Yield
-0.1
Market Cap
0,54 Bil.
Enterprise Value
0,50 Bil.
Graham Number
10.16
Graham NetNet
2.31

Income Statement Metrics

Net Income per Share
-1.65
Income Quality
0.77
ROE
-0.68
Return On Assets
-0.55
Return On Capital Employed
-0.7
Net Income per EBT
1
EBT Per Ebit
1.02
Ebit per Revenue
-104.49
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
27.17
Research & Developement to Revenue
70.64
Stock Based Compensation to Revenue
10.68
Gross Profit Margin
-53.22
Operating Profit Margin
-104.49
Pretax Profit Margin
-106.68
Net Profit Margin
-106.78

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.28
Free CashFlow per Share
-1.28
Capex to Operating CashFlow
-0
Capex to Revenue
0.04
Capex to Depreciation
0.08
Return on Invested Capital
-0.55
Return on Tangible Assets
-0.53
Days Sales Outstanding
1368.46
Days Payables Outstanding
41.83
Days of Inventory on Hand
0
Receivables Turnover
0.27
Payables Turnover
8.73
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
2,91
Book Value per Share
2,78
Tangible Book Value per Share
2.48
Shareholders Equity per Share
2.78
Interest Debt per Share
0.04
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.71
Current Ratio
5.27
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
0,10 Bil.
Invested Capital
114920000
Working Capital
0,10 Bil.
Intangibles to Total Assets
0.09
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-658999.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oculis Holding AG Dividends
Year Dividends Growth

Oculis Holding AG Profile

About Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

CEO
Dr. Riad Sherif M.B.A., M.D.
Employee
36
Address
Bahnhofstrasse 7
Zug, 6300

Oculis Holding AG Executives & BODs

Oculis Holding AG Executives & BODs
# Name Age
1 Mr. Daniel S. Char J.D.
Chief Legal Officer
70
2 Dr. Snehal Shah Pharm.D.
President of Research & Development
70
3 Ms. Virginia R. Dean
Chief Human Resources Officer
70
4 Ms. Rebecca Weil
Chief Commercial Officer
70
5 Dr. Ramin Tadayoni M.D., Ph.D.
Chief Scientific Officer
70
6 Mr. Páll Ragnar Jóhannesson
Chief Business Officer
70
7 Ms. Gudrun Bachmann Ph.D.
Chief Technology Officer
70
8 Dr. Sharon Klier M.D., M.P.H.
Chief Development Officer
70
9 Dr. Riad Sherif M.B.A., M.D.
Chief Executive Officer & Director
70
10 Ms. Sylvia Cheung
Chief Financial Officer
70

Oculis Holding AG Competitors